Latest Breaking News On - Transplantation unit - Page 1 : comparemela.com

ABIONYX Pharma RACERS Study Data in Sepsis Presented at the American Society of Nephrology (ASN) 2023 Annual Meeting Kidney Week

ABIONYX Pharma RACERS Study Data in Sepsis Presented at the American Society of Nephrology (ASN) 2023 Annual Meeting Kidney Week
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesCyrille tupinArthur rouillLoreto gesualdoLouis victor delouvrierNicolas fossiezRoveran gengaUniversity of bari aldo moroAmerican society of nephrologyNature springerAmerican societyKidney weekRelative risk reductionTransplantation unitBari aldo moroAcute kidney injury

World Sepsis Day September 13, 2023: ABIONYX Pharma Confirms Its Commitment to Sepsis, a Global Public Health Issue

World Sepsis Day September 13, 2023: ABIONYX Pharma Confirms Its Commitment to Sepsis, a Global Public Health Issue
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Baden wübergLoreto gesualdoNicolas fossiezAntonio crovaceArthur rouillPierre piorrySalvatore grassoLouis victor delouvrierUniversity of bariDepartment of nephrologyWorld sepsisScientific reportsAntimicrobial resistanceProfessor loreto gesualdoTemporary authorizationNamed use

CER-001 identified as potential treatment for septic patients

A Phase II pilot study demonstrated CER-001 is a potentially game-changing treatment for septic patients at high risk of acute kidney injury.

Loreto gesualdoConnie peyrottesUniversity of bari aldo moroProfessor loreto gesualdoTransplantation unitBari aldo moroKidney diseaseImproving global outcomesHigh density lipoprotein

ABIONYX Pharma Reports Positive Results from Phase 2a Pilot Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury

Positive results on primary and secondary endpoints, identifying dose for future development Direct and significant effect of CER-001 on endotoxin removal and consequent reduction in the inflammatory

Loreto gesualdoAntonio crovaceNicolas fossiezConnie peyrottesArthur rouillLouis victor delouvrierMichael davidsonSalvatore grassoUniversity of bari aldo moroUniversity of bariAcute kidney injuryTransplantation unitBari aldo moroKidney diseaseImproving global outcomesHigh density lipoprotein

ABIONYX Pharma: ABIONYX Announces Final Patient Enrollment in Phase 2a Clinical Trial with CER-001, Bio-HDL for the Treatment of Patients with Sepsis at High Risk of Developing Acute Kidney Injury

Top line results by late fall 2022 A potentially modifying effect on the progression of the inflammatory cascade in sepsis Regulatory News: ABIONYX Pharma, (FR0012616852 ABNX eligible

United statesLoreto gesualdoArthur rouillNicolas fossiezLouis victor delouvrierUniversity of bari aldo moroUniversity of bariFull professorTransplantation unitBari aldo moroSequential organ failure assessmentVictor delouvrier